Edoxaban for 12 Months Versus 3 Months in Patients With Cancer With Isolated Distal Deep Vein Thrombosis (ONCO DVT Study): An Open-Label, Multicenter, Randomized Clinical Trial
Yugo Yamashita,Takeshi Morimoto,Nao Muraoka,Takuya Oyakawa,Michihisa Umetsu,Daijirou Akamatsu,Yuji Nishimoto,Yukihito Sato,Takuma Takada,Kentaro Jujo,Yuichiro Minami,Yoshito Ogihara,Kaoru Dohi,Masashi Fujita,Tatsuya Nishikawa,Nobutaka Ikeda,Go Hashimoto,Kazunori Otsui,Kenta Mori,Daisuke Sueta,Yukari Tsubata,Masaaki Shoji,Ayumi Shikama,Yutaka Hosoi,Yasuhiro Tanabe,Ryuki Chatani,Kengo Tsukahara,Naohiko Nakanishi,Kitae Kim,Satoshi Ikeda,Makoto Mo,Yusuke Yoshikawa,Takeshi Kimura,ONCO DVT Study Investigators
DOI: https://doi.org/10.1161/CIRCULATIONAHA.123.066360
IF: 37.8
2023-11-21
Circulation
Abstract:Background: The optimal duration of anticoagulation therapy for isolated distal deep vein thrombosis in patients with cancer is clinically relevant, but the evidence is lacking. The prolonged anticoagulation therapy could have a potential benefit for prevention of thrombotic events; however, it could also increase the risk of bleeding. Methods: In a multicenter, open-label, adjudicator-blinded, randomized clinical trial at 60 institutions in Japan, we randomly assigned patients with cancer with isolated distal deep vein thrombosis, in a 1-to-1 ratio, to receive either a 12-month or 3-month edoxaban treatment. The primary end point was a composite of a symptomatic recurrent venous thromboembolism (VTE) or VTE-related death at 12 months. The major secondary end point was major bleeding at 12 months, according to the criteria of the International Society on Thrombosis and Haemostasis. The primary hypothesis was that a 12-month edoxaban treatment was superior to a 3-month edoxaban treatment with respect to the primary end point. Results: From April 2019 through June 2022, 604 patients were randomized, and after excluding 3 patients who withdrew consent, 601 patients were included in the intention-to-treat population: 296 patients in the 12-month edoxaban group and 305 patients in the 3-month edoxaban group. The mean age was 70.8 years, 28% of the patients were men, and 20% of the patients had symptoms of deep vein thrombosis at baseline. The primary end point of a symptomatic recurrent VTE event or VTE-related death occurred in 3 of the 296 patients (1.0%) in the 12-month edoxaban group and in 22 of the 305 patients (7.2%) in the 3-month edoxaban group (odds ratio, 0.13; 95% CI, 0.03-0.44). The major secondary end point of major bleeding occurred in 28 of the 296 patients (9.5%) in the 12-month edoxaban group and in 22 of the 305 patients (7.2%) in the 3-month edoxaban group (odds ratio, 1.34; 95% CI, 0.75-2.41). The prespecified subgroups did not affect the estimates on the primary end point. Conclusions: In patients with cancer with isolated distal deep vein thrombosis, 12 months was superior to 3 months for an edoxaban treatment with respect to the composite outcome of a symptomatic recurrent VTE or VTE-related death. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT03895502.